CEBPA and acute myeloid leukemia: C/EBPα dysregulation plays a significant role in AML: approximately half of cases have a reduction in CEBPA mRNA compared to normal myeloid progenitors,31,32 and loss-of-function mutations have been reported in 5%–10% of patients.33